Gilead continues small deal spree
Gilead buys a stake in Pionyr and holds the option to acquire the biotech outright.
Gilead buys a stake in Pionyr and holds the option to acquire the biotech outright.
The partners extend an existing collaboration to develop mRNA vaccines against infectious diseases.
Orca Bio emerges with a manufacturing platform that it claims produces cell therapies with an ‘unprecedented turnaround time’.